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One sentence summary: This study documented Chlamydia pneumoniae in 4.9% of children with cystic fibrosis, stressing the need for routine screening,
and investigated its impact on airway microbiota by 16S amplicon-based metagenomics.




Objectives: The contribution of intracellular and fastidious bacteria in Cystic fibrosis (CF) pulmonary exacerbations, and
progressive lung function decline remains unknown. This project aimed to explore their impact on bacterial microbiota
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diversity over time in CF children. Methods: Sixty-one children enrolled in the MUCOVIB multicentre prospective cohort
provided 746 samples, mostly nasopharyngeal swabs, throat swabs and sputa which were analysed using culture, specific
real-time qPCRs and 16S rRNA amplicon metagenomics. Results: Chlamydia pneumoniae (n = 3) and Mycoplasma pneumoniae
(n = 1) were prospectively documented in 6.6% of CF children. Microbiota alpha-diversity in children with a documented C.
pneumoniae was highly variable, similarly to children infected with Staphylococcus aureus or Pseudomonas aeruginosa. The
transition from routine follow-up visits to pulmonary exacerbation (n = 17) yielded variable changes in diversity indexes
with some extreme loss of diversity. Conclusions: The high rate of C. pneumoniae detection supports the need for regular
screenings in CF patients. A minor impact of C. pneumoniae on the microbial community structure was documented.
Although detected in a single patient, M. pneumoniae should also be considered as a possible aetiology of lung infection in
CF subjects.
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INTRODUCTION
Cystic fibrosis (CF) is a common genetic disorder, character-
ized by chronic inflammation and repeated bacterial pulmonary
infections leading to pulmonary exacerbations (PEs). Despite
recent advances in the understanding of the role of the respi-
ratory microbiota constituents on disease progression (O’Toole
2018), the prevalence and impact of respiratory viruses, intra-
cellular bacteria (such as Chlamydia pneumoniae) and fastidious
organisms (such as Mycoplasma pneumoniae) remain poorly doc-
umented.
While earlier studies essentially focused on pyogenic
pathogenic bacteria, the development of metagenomic anal-
yses emphasized the role of complex ecological interactions
within the microbiota (O’Toole 2018). CF airways typically harbor
early formed complex microbial communities with large inter-
patient variability (Huang and LiPuma 2016). Yet, a complete
understanding of the impact of individual pathogens on res-
piratory bacterial microbiota is currently lacking. New models
must take into account polymicrobial infections in biofilm-like
structures that may better represent the airway microbiota in CF
(O’Toole 2018). These new models must consider dominant bac-
terial species, but also viruses and M. pneumoniae or C. pneumo-
niae, which could affect the host directly or indirectly by interact-
ing with other pathogens of the microbial community (Hajishen-
gallis et al. 2011; de Dios Caballero et al. 2017).
The impact of M. pneumoniae and C. pneumoniae has already
been reported in a wide range of respiratory syndromes, includ-
ing community-acquired pneumonia and asthma exacerbations
(Emre et al. 1995; Welti et al. 2003; Lamoth and Greub 2010; Senn
et al. 2011; Asner et al. 2014; Parrott, Kinjo and Fujita 2016; Webley
and Hahn 2017). Limited publications reported on the prevalence
of C. pneumoniae and M. pneumoniae in CF patients (Petersen et al.
1981; Emre et al. 1996), likely as a result of small pediatric cohorts
in individual centers and the use of culture and serology rather
than molecular assays. In addition, screening for these microor-
ganisms by molecular assays is often only considered when res-
piratory tract infections lead to severe complications such as
pericarditis rather than routinely (Esposito et al. 2006). The use
of metagenomics-based assays might offer more insights on the
incidence and the prevalence of these bacteria in CF.
The aim of this MUCOVIB sub-study was to report on the
prevalence of C. pneumoniae and M. pneumoniae and their impact
on the respiratory microbiota of children with CF, by using
a specific multiplex quantitative PCR and 16S amplicon-based
metagenomics. Their potential impact on overall bacterial diver-
sity before PE, during exacerbation events, and during routine
follow-up was also investigated.
METHODS
The MUCOVIB cohort and sampling
The MUCOVIB project is a longitudinal multicentre prospec-
tive cohort study involving all children under 18 years with
CF followed at University Hospitals of Lausanne and Geneva,
Switzerland. Respiratory samples, including throat swabs (TS),
nasopharyngeal swabs (NPS) and sputa (EXP; when able to
expectorate), were collected during routine visits and PEs requir-
ing hospital admission from April 2016 to June 2018. PE were
defined according to Rosenfeld et al.’s definition (Rosenfeld et al.
2001). Relevant clinical and laboratory data were also collected
at each visit.
Bacterial culture and quantitative PCRs
Standard bacterial cultures were performed on both TS and
EXP samples, when available. NPS were tested by qPCR for
the detection of Mycoplasma pneumoniae and Chlamydia pneumo-
niae, as previously described (Welti et al. 2003; Senn et al. 2011;
Greub et al. 2016). Briefly, DNA was extracted with a MagNA
Pure system (Roche Life Science). A multiplex quantitative real-
time TaqMan PCR (qPCR) allowed to quantify M. pneumoniae
and C. pneumoniae DNA in copies/ml using a calibrated posi-
tive plasmid control. In patients with a positive NPS Chlamy-
dia or Mycoplasma qPCR, all other samples available (TS and/or
EXP) were subsequently tested using the same qPCR described
above.
16S rRNA metagenomics analyses
Libraries of 16S rRNA V3-V4 amplicons were prepared according
to the 16S Metagenomic Sequencing Library Preparation (Part.
# 15044223 Rev. B) protocol and sequenced at the Institute of
Microbiology of the University of Lausanne using a MiSeq (Illu-
mina, San Diego, USA). Positive (ATCC-2002 mock community)
and negative controls for DNA extraction and library prepara-
tion using DNA free water were included in each sequencing
run. Samples with less than 5 nM DNA after PCR amplification
or less than 20,000 reads were not used for further analyses.
Sequences were attributed to Amplicon Sequence Variant (ASVs)
by a home-made pipeline (v.0.9.11) based on DADA2 (1.12.1)
(Callahan et al. 2016) and taxonomically assigned using the Ribo-
somal Database Project classifier (Wang et al. 2007) in Qiime 1.9.1
(Caporaso et al. 2010) against the EzBioCloud reference database
(05.2018) (Yoon et al. 2017). Bacterial alpha-diversity was mea-
sured after rarefying to 20 000 sequences per sample. Shannon
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index, which accounts for both species richness (number of
species) and evenness (relative abundance of species) and the
Chao1 index, which only accounts for species richness, were cal-
culated with Phyloseq R package (1.28.0) (McMurdie and Holmes
2013). All statistical analyses and visualizations were carried out
in the R environment (v. 3.3.3) (R Core Team 2019). Raw sequenc-
ing reads were deposited in the European Nucleotide Archive
(ENA) under the project number PRJEB41059.
RESULTS
Bacterial distribution within the MUCOVIB cohort
From April 2016 to June 2018, 61 patients were included with a
median age of 7.4 years old (interquartile range (IQR): 3.7–12.2).
During follow-up, 20 patients (33%) presented at least one docu-
mented PE resulting in a total of 32 PE events. During 1 to 9 visits
(IQR: 5–8), a total of 366 samples, including 309 TS, 52 sputa sam-
ples and 5 NPS were successfully analysed by 16S rRNA metage-
nomics and 363 NPS by qPCRs. From the 30 TS and EXP col-
lected during 24 PE events, 21 samples were analyzed by bacte-
rial culture. Bacterial pathogens were detected from 15 samples
including Staphylococcus aureus (n = 4), H. influenzae (n = 2), and
mixed bacteria corresponding to any combination of S. aureus,
P. aeruginosa, H. influenzae and/or other remaining pathogens,
which essentially included Streptococci (n = 9). A total of 293 TS
and EXP collected during 315 follow-up visits were analysed by
bacterial culture, of which 167 were tested positive for S. aureus
(n = 99), mixed bacteria (n = 37), single other bacteria (n = 19), P.
aeruginosa (n = 9) and H. influenzae (n = 3).
During the study period, 4 patients presented with an intra-
cellular bacteria or fastidious organism infection, none of them
receiving any prophylactic antibiotic. C. pneumoniae was docu-
mented from 3 patients by qPCR, in higher quantity from NPS
compared to TS (Table 1 and Fig. 1C), albeit the highest quan-
tity of C. pneumoniae DNA was reported from a sputum sample
collected from the single patient able to expectorate.
Descriptive characteristics and outcomes of study
subjects with C. pneumoniae and M. pneumoniae
documented from their respiratory samples
Table 1 summarizes clinical symptoms and outcomes in addi-
tion to viral and bacterial pathogens identified in samples from
children with documented C. pneumoniae and M. pneumoniae.
The first patient was co-infected by C. pneumoniae and a rhi-
novirus, while being asymptomatic. The second symptomatic
patient had a documented C. pneumoniae infection with no other
bacterial or viral pathogen identified. His lung clearance index
increased from 7 to 11, thereby suggesting an acute deterio-
ration of his lung function albeit without criteria for a PE. He
was treated with clarithromycin. The third patient presented
with pharyngitis and a productive cough, with high loads of
C. pneumoniae documented by qPCR from EXP, NPS and TS,
still detectable 2 months later, despite being treated with a
macrolide. He also presented an increase in his lung clearance
index from 7 to 10.1. A co-infection with rhinovirus, S. aureus
and H. influenzae was reported from his initial EXP sample, while
only low load (102 copies/ml) of S. aureus was documented from
his 2-month follow-up EXP sample. M. pneumoniae was docu-
mented from only one symptomatic child in co-infection with
coronavirus OC43 and human metapneumovirus. Moreover, a
moderate load of methicillin-sensitive S. aureus was recovered
from his TS. His symptoms resolved after being treated with co-
amoxicillin and clarithromycin (Table 1).
Measures of microbial diversity in children
documented with C. pneumoniae and M. pneumoniae
To assess whether C. pneumoniae or M. pneumoniae impact on
microbial diversity, two alpha-diversity indexes, namely, Chao1
index, which reflects species richness, and Shannon index,
which accounts for both species richness and evenness, were
calculated based on ASV counts in TS. Figure 1 A/B displays
Shannon and Chao1 indexes according to the documentation
of S. aureus, P. aeruginosa or other bacteria by bacterial cultures
or C. pneumoniae and M. pneumoniae identified by qPCR during
routine follow-up visits (grey dots) or PEs (red dots). To avoid
the over-representation of patients with multiple follow-up vis-
its, only one TS per patient in a routine follow-up visit, and
one in a PE event was randomly selected for each category of
pathogen. No difference in alpha diversity indexes was docu-
mented from TS collected from patients in whom C. pneumo-
niae or M. pneumoniae were reported compared to those collected
from children infected with S. aureus or P. aeruginosa. The tran-
sition from routine follow-up visits to PE (n = 17 documented)
yielded both increased or decreased diversity depending on the
patient and visit, with some extreme loss of diversity (maximum
Shannon and Chao1 change of −1.73 and −177.3, respectively).
Shannon mean change in transitions to PE was −0.14 (IQR − 0.66
to 0.29) whereas Chao1 mean change was of −18.6 (IQR −28.8
to 8.5). Slightly decreased alpha indexes measures were docu-
mented during S. aureus PE (with or without P. aeruginosa), albeit
not statistically significantly, likely as a result of the small num-
ber of events. Chao1 and Shannon indexes were similar during
PE events as during routine follow-up visits for mixed infections
and other bacteria.
Next, the ability of 16S rRNA metagenomics assays to detect
C. pneumoniae and M. pneumoniae was evaluated (Fig. 1C). In
metagenomics analyses, up to 30% of 16S rRNA sequences were
assigned to C. pneumoniae in NPS (n = 4). However, TS (n = 5) and
EXP (n = 1) samples positive by qPCR reported lowly abundant
C. pneumoniae and M. pneumoniae sequences, ranging from 0.01%
to 3.1% and 0.035% of 16S rRNA sequences, respectively (Fig. 1C).
In one TS sample, C. pneumoniae reads were identified only using
operational taxonomic unit (OTU) clustering (97% identity), data
not shown) but not using ASVs, even without rarefaction. These
results highlight the small proportion of C. pneumoniae and M.
pneumoniae species in throat swabs. Both C. pneumoniae and M.
pneumoniae only encode for one copy of the 16S rRNA gene tar-
geted by the PCR used for the present metagenomics analyses,
which might contribute to their weak detection by 16S rRNA
metagenomics.
The low abundance of sequencing reads attributed to C.
pneumoniae and M. pneumoniae contrasted with a subset of S.
aureus induced PE in which S. aureus was documented as the
predominant bacterial species during a PE (Fig. 1E). In this
case, the decreased proportion of various microbial species
and increased amount of S. aureus was documented 3 months
prior to exacerbation (Fig. 1E), thus questioning whether the
use of metagenomics could allow to anticipate episodes of PE.
In contrast, other children with P. aeruginosa and/or S. aureus
PE documented by bacterial culture exhibited low abundance
of sequences attributed to their respective pathogens at time
of exacerbation (Fig. 1F), with a rather conserved microbial
diversity.
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pneumoniae Sample type Copies/ml
Other microorganisms
documented Treatment
1 Asymptomatic C. pneumoniae NPS 11 220 000 RV None
TS 675 000




C. pneumoniae EXP 82 270 000 RV Clarithromycin
NPS 1 891 000 104 S. aureus bacteria/ml
TS 46 000 104 H. influenzae
bacteria/ml
4 Rhinorrhea, dry cough M. pneumoniae NPS 2370 OC43; hMPV Co-amoxicillin,
clarithromycin
TS N/A S. aureus 102 cp/ml
Legend: Rhinovirus (RV); Coronavirus OC43 (OC43), human metapneumovirus (hMPV); nasopharyngeal swabs (NPS); throat swabs (TS); Sputa samples (EXP).
DISCUSSION
As part of the MUCOVIB study, we documented C. pneumoniae
or M. pneumoniae infections in 6.6% of all children with CF of
whom 75% presented with upper respiratory tract (URT) symp-
toms despite not meeting criteria for a PE. The 4.9% (3/61) rate
of C. pneumoniae documented in CF is significantly higher than
the 0.13% prevalence of C. pneumoniae positive PCRs previously
reported from all patients using the same PCR (Senn et al. 2011),
but lower than the 12.5% (4/32) rate previously reported in CF
children with PE using culture and serology (Emre et al. 1996).
Furthermore, only one third (19/61) of our CF cohort was on a
macrolide prophylaxis during the study period. Only one patient
was detected positive for M. pneumoniae, resulting in a 1.6%
prevalence, which was similar to that reported in a recent Swiss
study of children with respiratory tract infections (Dierig et al.
2020), and a report from the 1980s in CF patients (Petersen et al.
1981). This high rate of C. pneumoniae detection in children with
CF is in line with the previous reports (Petersen et al. 1981;
Emre et al. 1996), and supports the need for a systematic detec-
tion during regular visits by using a chlamydia qPCR. As such,
a better estimation of the prevalence of C. pneumoniae in CF
patients coupled with a better understanding of their reciprocal
inferences with CF respiratory microbiota might provide addi-
tional insight into the pathogenesis of CF chronic inflammation.
As these obligate intracellular organisms are not susceptible to
antibiotics usually prescribed during CF PE, they result in pro-
longed clinical symptoms requiring longer antibiotic treatments
with macrolides (Hammerschlag et al. 1992). ‘Traditional’ antibi-
otics typically impact on bacterial microbiota diversity, which
could change one’s susceptibility to these not-targeted micro-
organisms. Furthermore, long-term prescription of macrolide
among patients with CF has resulted in improvement of respira-
tory function and reduction of PE episodes, without fully under-
standing the exact underlying mechanisms (Southern et al.
2012). In this regard, documentation and treatment of occult
intracellular bacteria might impact progressive lung function
decline (Janahi et al. 2005). Given the higher loads of C. pneu-
moniae documented from NPS compared to TS, the use of NPS
should be privileged.
Using a limited number of samples, no impact of C. pneumo-
niae or M. pneumoniae on Shannon or Chao1 diversity indexes
as compared to S. aureus and/or P. aeruginosa-positive TS was
documented in our cohort. Interestingly, changes in microbial
diversity were generally observed between routine follow-up
visits and PE. Whether these changes have an impact on the
susceptibility to infections with C. pneumoniae and M. pneumo-
niae is unknown. Our observations suggest a minor impact of C.
pneumoniae on the microbial community structure. However, the
small number of samples and the high inter-individual diver-
sity, limited our analyses to measures of alpha-diversity indexes
only. Future larger datasets should also consider the evalua-
tion of changes in bacterial composition and taxonomy by using
beta-diversity indexes. Future study should also aim to evaluate
to what extent changes in the structure of the respiratory micro-
bial community, over time or due to antibiotic treatment, have
an impact on the susceptibility to infections with C. pneumoniae
and M. pneumoniae.
Metagenomics profiling might allow both the study of
changes in the microbiota structure and the analysis of specific
established human pathogen, including M. pneumoniae and C.
pneumoniae. Yet, while the qPCR was sensitive enough to detect
chlamydial DNA in all sample types (NPS, TS and EXP), only a
few reads classified as C. pneumoniae were detected by 16S-based
metagenomics in EXP and TS. This suggests that a large propor-
tion of other microbial species in the airway microbiome may
potentially hide significant intracellular or fastidious pathogens
in metagenomics analyses. Intracellular bacteria with particu-
larly small genomes such as C. pneumoniae or M. pneumoniae only
harbour one copy of the 16S rRNA (Kalman et al. 1999; Klap-
penbach, Dunbar and Schmidt 2000) targeted for amplification
and may thereby be more difficult to detect than other com-
mon pathogens. These observations support the need for suf-
ficient sequencing coverage and suggest the risk of analyses on
rarefied data, specifically when they are not coupled with doc-
umentation of pathogens by other methods. In addition, the
low amount of chlamydia sequences highlights the importance
of the 16S PCR amplification prior to NGS analyses and ques-
tions the potential sensitivity of shotgun metagenomics for such
cases.
As previously documented in CF patients (Zhao et al. 2012;
Carmody et al. 2015), common pathogens such as S. aureus or
P. aeruginosa have become a major component of the bacterial
microbiota only in some cases (Fig. 1). Regular metagenomics
profiling could allow to evaluate the overgrowth of a pathogen
and potentially to anticipate PE. Microbial communities were to
some extent resilient to PE and antibiotic treatment, but major,
stable changes in composition were also documented. While




Figure 1. 16S rRNA amplicon metagenomics of CF patients. (A), Shannon index of diversity, taking into account both the number of amplicon sequence variants
(ASVs) and their relative abundance, and (B) Chao1 index of diversity, taking into account number of ASVs, in throat swabs of follow-up visits according to the bacteria
documented by qPCR (Chlamydia pneumoniae (Cpn) and Mycoplasma pneumoniae (Mpn)) or culture (Pseudomonas aeruginosa (Paer), Staphylococcus aureus (Saur), or both
(Saur + Paer), as well as other pathogens or mixed infections of P. aeruginosa and S. aureus with other bacteria (Others)). The diversity index during episodes of
documented PE is overlaid with red points. (C), Relative abundance of bacterial genera present in expectorations (EXP), nasopharyngeal swabs (NPS) and throat swabs
(TS) of the three patients with documented C. pneumoniae. (D), Relative abundance of bacterial genera in TS along time for one patient with a documented symptomatic
C. pneumoniae infection at visit V01 (middle patient in panel C). Chlamydia sequences remained lowly abundant (0.01%) in the TS and are hence not visible among other
more prevalent (>1%) bacterial species. (E), Relative abundance of bacterial genera in expectorations along time for one patient with a symptomatic infection due to S.
aureus. The impressive increase in S. aureus proportion can be seen by metagenomics before symptoms arose. (F), Relative abundance of bacterial genera in TS along
time for one patient with a symptomatic infection to P. aeruginosa and S. aureus, that appeared in small proportion before decreasing in the follow-up visits. In panel
D, E and F, episodes of PE are underlined in red on the x axis.
larger-scale studies are obviously needed to better model the
effect of intracellular and fastidious bacteria, overall changes
in diversity may be difficult to detect, as the baseline diversity
varies among patients and decreases with time along disease
progression.
In conclusion, while our sample size was too limited to infer
any association between presence of C. pneumoniae or M. pneu-
moniae and changes in bacterial microbiota composition over
time, the observed high rate of positivity for C. pneumoniae (4.9%)
suggests that children with CF should be routinely screened
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from NPS rather than TS and adequately treated for C. pneu-
moniae. In addition, further large-scale multicentre studies will
better delineate the impact of these fastidious and intracellular
pathogens on the bacterial alpha and beta-diversity over time,
as well as the impact of the change in the bacterial diversity on
the susceptibility to infections with C. pneumoniae and M. pneu-
moniae.
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